68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer

Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study

Michael S. Hofman, Nathan Lawrentschuk, Roslyn J. Francis et al. · The Lancet · 2020 · 2K citations

Medicine, Nuclear Medicine, Oncology +17

Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)

M. Bolla, Bertrand Tombal, K. Vekemans et al. · The Lancet · 2012 · 864 citations

Medicine, Surgery, Urology +11

68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour

Christian Uprimny, Alexander Kroiss, Clemens Decristoforo et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2017 · 342 citations

Medicine, Nuclear Medicine, Oncology +17

Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis

Marie C. Hupe, Christian Philippi, Doris Roth et al. · Frontiers in Oncology · 2018 · 179 citations · Full text

Medicine, Oncology, Urology +17

3-Year Freedom from Progression After ⁶⁸Ga-PSMA PET/CT–Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial

Louise Emmett, Reuben Tang, Rohan Nandurkar et al. · Journal of Nuclear Medicine · 2019 · 148 citations · Full text

Medicine, Nuclear Medicine, Urology +17